Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.45 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365202 | 1.00 | SRD5A2 (0.45) | SRD5A2SRD5A1AKR1B1TBXA2RALDH1A1 | |
| SCHEMBL4365208 | 1.00 | SRD5A2 (0.45) | SRD5A2SRD5A1AKR1B1TBXA2RALDH1A1 | |
| SCHEMBL1917164 | 0.87 | MAPK14 (0.45) | AKR1B1ALDH1A1MAPTSMN1; SMN2MAPK14 | |
| SCHEMBL1917165 | 0.87 | MAPK14 (0.45) | AKR1B1ALDH1A1MAPTSMN1; SMN2MAPK14 | |
| SCHEMBL1917168 | 0.87 | MAPK14 (0.45) | AKR1B1ALDH1A1MAPTSMN1; SMN2MAPK14 | |
| SCHEMBL15301639 | 0.81 | NOTUM (0.46) | SRD5A2SRD5A1TBXA2RALDH1A1 | |
| SCHEMBL15301638 | 0.81 | NOTUM (0.46) | SRD5A2SRD5A1TBXA2RALDH1A1 | |
| SCHEMBL15301637 | 0.81 | NOTUM (0.46) | SRD5A2SRD5A1TBXA2RALDH1A1 | |
| SCHEMBL490046 | 0.80 | AKR1B1 (0.65) | SRD5A2SRD5A1AKR1B1ALDH1A1MAPT | |
| SCHEMBL15301425 | 0.80 | SRD5A2 (0.45) | SRD5A2SRD5A1AKR1B1TBXA2RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1988091-B1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-8242151-B2 | Tricyclic compounds | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1988091-A1 | TRICYCLIC COMPOUNDS | Kyowa Hakko Kogyo Co., Ltd (JP) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | PPARG, PPARD, PPARA | SRD5A2 737/4885SRD5A1 816/4885AKR1B1 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.